Endovascular Recanalization Therapy in Acute Ischemic Stroke: Updated Meta-analysis of Randomized Controlled Trials
2
조회
0
다운로드
12
인용
0
참고문헌
키워드
초록
Background and Purpose Recent randomized clinical trials (RCTs) have demonstrated benefits of endovascular recanalization therapy (ERT) contrary to earlier trials. We aimed to estimate the benefits of ERT added to standard therapy in acute ischemic stroke. Methods From a literature search of RCTs testing ERT, we performed a meta-analysis to estimate an overall efficacy and safety of ERT for all trials, stent-retriever trials, and RCTs comparing ERT and intravenous tissue plasminogen activator (IV-TPA). Results We identified 15 relevant RCTs including 2,899 patients. For all trials, ERT was associated with increased good outcomes (odds ratio [OR] 1.79; 95% confidence interval [CI] 1.34, 2.40; P<0.001) compared to the control. ERT also increased no or minimal disability outcomes, good neurological recovery, good activity of daily living, and recanalization. ERT did not significantly increase symptomatic intracranial hemorrhage (SICH) (OR 1.19; 95% CI 0.83, 1.69; P=0.345) or death (OR 0.87; 95% CI 0.71, 1.05; P=0.151). In contrast, ERT significantly reduced extreme disability or death (OR 0.77; 95% CI 0.61, 0.97; P=0.025). Restricting to five stent-retriever trials comparing ERT plus IV-TPA vs. IV-TPA alone, the benefit was even greater for good outcome (OR 2.39; 95% CI 1.88, 3.04; P<0.001) and extreme disability or death (OR 0.57; 95% CI 0.41, 0.78; P=0.001). Restricting to eight RCTs comparing ERT (plus IV-TPA in six trials) with IV-TPA alone showed similar efficacy and safety. Conclusions This updated meta-analysis shows that ERT substantially improves clinical outcomes and reduces extreme disability or death without significantly increasing SICH compared to standard therapy.
Abstract
Background and Purpose Recent randomized clinical trials (RCTs) have demonstrated benefits of endovascular recanalization therapy (ERT) contrary to earlier trials. We aimed to estimate the benefits of ERT added to standard therapy in acute ischemic stroke. Methods From a literature search of RCTs testing ERT, we performed a meta-analysis to estimate an overall efficacy and safety of ERT for all trials, stent-retriever trials, and RCTs comparing ERT and intravenous tissue plasminogen activator (IV-TPA). Results We identified 15 relevant RCTs including 2,899 patients. For all trials, ERT was associated with increased good outcomes (odds ratio [OR] 1.79; 95% confidence interval [CI] 1.34, 2.40; P<0.001) compared to the control. ERT also increased no or minimal disability outcomes, good neurological recovery, good activity of daily living, and recanalization. ERT did not significantly increase symptomatic intracranial hemorrhage (SICH) (OR 1.19; 95% CI 0.83, 1.69; P=0.345) or death (OR 0.87; 95% CI 0.71, 1.05; P=0.151). In contrast, ERT significantly reduced extreme disability or death (OR 0.77; 95% CI 0.61, 0.97; P=0.025). Restricting to five stent-retriever trials comparing ERT plus IV-TPA vs. IV-TPA alone, the benefit was even greater for good outcome (OR 2.39; 95% CI 1.88, 3.04; P<0.001) and extreme disability or death (OR 0.57; 95% CI 0.41, 0.78; P=0.001). Restricting to eight RCTs comparing ERT (plus IV-TPA in six trials) with IV-TPA alone showed similar efficacy and safety. Conclusions This updated meta-analysis shows that ERT substantially improves clinical outcomes and reduces extreme disability or death without significantly increasing SICH compared to standard therapy.
참고문헌 (30)
- "Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group", N Engl J Med, 333, pp.1581~1587 (1995)
- Hacke W, "Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke", N Engl J Med, 359, pp.1317~1329 (2008)
- Riedel CH, "The importance of size: successful recanalization by intravenous thrombolysis in acute anterior stroke depends on thrombus length", Stroke, 42, pp.1775~1777 (2011)
- Broderick JP, "Endovascular therapy after intravenous t-PA versus t-PA alone for stroke", N Engl J Med, 368, pp.893~903 (2013)
- Lee M, "Efficacy of intra-arterial fibrinolysis for acute ischemic stroke: meta-analysis of randomized controlled trials", Stroke, 41, pp.932~937 (2010)
- Ciccone A, "Endovascular treatment for acute ischemic stroke", N Engl J Med, 368, pp.904~913 (2013)
- Berkhemer OA, "A randomized trial of intraarterial treatment for acute ischemic stroke", N Engl J Med, 372, pp.11~20 (2015)
- Goyal M, "Randomized assessment of rapid endovascular treatment of ischemic stroke", N Engl J Med, 372, pp.1019~1030 (2015)
- Campbell BC, "Endovascular therapy for ischemic stroke with perfusion-imaging selection", N Engl J Med, 372, pp.1009~1018 (2015)
- Saver JL, "Stent-Retriever Thrombectomy after Intravenous t-PA vs. t-PA Alone in Stroke", N Engl J Med, 372, pp.2285~2295 (2015)
- Jovin TG, "Thrombectomy within 8 Hours after Symptom Onset in Ischemic Stroke", N Engl J Med, 372, pp.2296~2306 (2015)
- Higgins JPT, "Cochrane Handbook for Systematic Reviews of Interventions: West Sussex" (2008), Cochrane Collaboration and John Wiley & Sons Ltd
- Furlan A, "Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism", JAMA, 282, pp.2003~2011 (1999)
- del Zoppo GJ, "PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism", Stroke, 29, pp.4~11 (1998)
- Keris V, "Combined intraarterial", intravenous thrombolysis for acute ischemic stroke, 2001, pp.22, 352~358
- Ducrocq X, "Comparison of intravenous and intra-arterial urokinase thrombolysis for acute ischaemic stroke", J Neuroradiol, 32, pp.26~32 (2005)
- Macleod MR, "Results of a multicentre, randomised controlled trial of intra-arterial urokinase in the treatment of acute posterior circulation ischaemic stroke", Cerebrovasc Dis, 20, pp.12~17 (2005)
- Ogawa A, "Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: the middle cerebral artery embolism local fibrinolytic intervention trial (MELT) Japan", Stroke, 38, pp.2633~2639 (2007)
- Ciccone A, "Intra-arterial or intravenous thrombolysis for acute ischemic stroke? The SYNTHESIS pilot trial", J Neurointerv Surg, 2, pp.74~79 (2010)
- Kidwell CS, "A trial of imaging selection and endovascular treatment for ischemic stroke", N Engl J Med, 368, pp.914~923 (2013)
- Samsa GP, "Utilities for major stroke: results from a survey of preferences among persons at increased risk for stroke", Am Heart J, 136, pp.703~713 (1998)
- Hong KS, "Quantifying the value of stroke disability outcomes: WHO global burden of disease project disability weights for each level of the modified Rankin Scale", Stroke, 40, pp.3828~3833 (2009)
- Shuaib A, "NXY-059 for the treatment of acute ischemic stroke", N Engl J Med, 357, pp.562~571 (2007)
- Huynh T, "Comparison of Primary Percutaneous Coronary Intervention and Fibrinolytic Therapy in ST-Segment-Elevation Myocardial Infarction: Bayesian Hierarchical Meta-Analyses of Randomized Controlled Trials and Observational Studies", Circulation, 119, pp.3101~3109 (2009)
- Zahuranec DB, "Percentage of acute stroke patients eligible for endovascular treatment", Neurology, 79, pp.S22~S25 (2012)
- 홍근식, "Stroke Statistics in Korea: Part II Stroke Awareness and Acute Stroke Care, A Report from the Korean Stroke Society and Clinical Research Center For Stroke", 대한뇌졸중학회지, 15(2), pp.67~77 (2013), 대한뇌졸중학회[DOI]
- 김범준, "Case Characteristics, Hyperacute Treatment, and Outcome Information from the Clinical Research Center for Stroke-Fifth Division Registry in South Korea", 대한뇌졸중학회지, 17(1), pp.38~53 (2015), 대한뇌졸중학회
- Jung KH, "Secular trends in ischemic stroke characteristics in a rapidly developed country: results from the Korean Stroke Registry Study (secular trends in Korean stroke)", Circ Cardiovasc Qual Outcomes, 5, pp.327~334 (2012)
- Kim BJ, "Current status of acute stroke management in Korea: a report on a multicenter, comprehensive acute stroke registry", Int J Stroke, 9, pp.514~518 (2014)
- Hong KS, "Greater stroke severity predominates over all other factors for the worse outcome of cardioembolic stroke", J Stroke Cerebrovasc Dis, 22, pp.e373~380 (2013)